Michael Scharl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5616046/publications.pdf

Version: 2024-02-01

172 papers	13,344 citations	87888 38 h-index	23533 111 g-index
175 all docs	175 docs citations	175 times ranked	26225 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1982-1992.	1.9	565
4	Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut, 2017, 66, 1216-1224.	12.1	223
5	NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. Journal of Clinical Investigation, 2016, 126, 1783-1800.	8.2	171
6	Interleukin-13 and transforming growth factor Î² synergise in the pathogenesis of human intestinal fistulae. Gut, 2013, 62, 63-72.	12.1	108
7	Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis. Clinical and Translational Medicine, 2015, 4, 1.	4.0	108
8	Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis â€" An open pilot study. Journal of Crohn's and Colitis, 2013, 7, 271-279.	1.3	106
9	Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. PLoS ONE, 2016, 11, e0156666.	2.5	104
10	Protection of Epithelial Barrier Function by the Crohn's Disease Associated Gene Protein Tyrosine Phosphatase N2. Gastroenterology, 2009, 137, 2030-2040.e5.	1.3	100
11	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. Journal of Crohn's and Colitis, 2020, 14, 1503-1511.	1.3	100
12	AMP-activated Protein Kinase Mediates the Interferon-Î³-induced Decrease in Intestinal Epithelial Barrier Function. Journal of Biological Chemistry, 2009, 284, 27952-27963.	3.4	93
13	Pathophysiology of fistula formation in Crohn's disease. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 205.	1.0	93
14	Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. Journal of Crohn's and Colitis, 2016, 10, 377-386.	1.3	92
15	PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. Autophagy, 2017, 13, 1590-1601.	9.1	90
16	Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 200-206.	1.8	89
17	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2018, 12, 811-818.	1.3	88
18	PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. Cell Reports, 2018, 22, 1835-1848.	6.4	80

#	Article	IF	Citations
19	Protein tyrosine phosphatase N2 regulates TNFÂ-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut, 2011, 60, 189-197.	12.1	72
20	Inflammatory bowel disease pathogenesis. Current Opinion in Gastroenterology, 2012, 28, 301-309.	2.3	72
21	Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. EBioMedicine, 2019, 48, 648-655.	6.1	72
22	Protein Tyrosine Phosphatase non-Receptor Type 2 regulates IFN-Î³-induced cytokine signaling in THP-1 monocytes. Inflammatory Bowel Diseases, 2010, 16, 2055-2064.	1.9	71
23	CrohnÊ¼s disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflammatory Bowel Diseases, 2012, 18, 900-912.	1.9	71
24	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. PLoS ONE, 2016, 11, e0154817.	2.5	71
25	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host and Microbe, 2021, 29, 1573-1588.e7.	11.0	71
26	Vegetarian or glutenâ€free diets in patients with inflammatory bowel disease are associated with lower psychological wellâ€being and a different gut microbiota, but no beneficial effects on the course of the disease. United European Gastroenterology Journal, 2019, 7, 767-781.	3.8	67
27	Inflammatory Bowel Disease: Dysfunction of Autophagy?. Digestive Diseases, 2012, 30, 12-19.	1.9	65
28	Anti-MMP-9 Antibody. Inflammatory Bowel Diseases, 2016, 22, 2041-2057.	1.9	64
29	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. Clinical Gastroenterology and Hepatology, 2020, 18, 2019-2029.e11.	4.4	64
30	PTPN2 Regulates Interactions Between Macrophages and Intestinal Epithelial Cells to Promote Intestinal Barrier Function. Gastroenterology, 2020, 159, 1763-1777.e14.	1.3	62
31	Protein Tyrosine Phosphatase Nonreceptor Type 2 Regulates Autophagosome Formation in Human Intestinal Cells. Inflammatory Bowel Diseases, 2012, 18, 1287-1302.	1.9	60
32	Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS ONE, 2017, 12, e0185193.	2.5	54
33	Potential role for SNAIL family transcription factors in the etiology of CrohnÊ¼s disease-associated fistulae. Inflammatory Bowel Diseases, 2011, 17, 1907-1916.	1.9	51
34	Tofacitinib for the Treatment of Pyoderma Gangrenosum. Clinical Gastroenterology and Hepatology, 2019, 17, 991-993.	4.4	48
35	Malignancies in Inflammatory Bowel Disease. Digestion, 2020, 101, 136-145.	2.3	48
36	Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon-Î³â€“Induced Signaling in Human Monocytes. Gastroenterology, 2013, 144, 978-988.e10.	1.3	46

#	Article	IF	Citations
37	Expression Patterns of TNFÎ±, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 347-354.	1.3	44
38	Î²₆â€integrin serves as a novel serum tumor marker for colorectal carcinoma. International Journal of Cancer, 2019, 145, 678-685.	5.1	42
39	Upper Gastrointestinal Tract Involvement in Crohnâ€™s Disease: Frequency, Risk Factors, and Disease Course. Journal of Crohn's and Colitis, 2018, 12, 1399-1409.	1.3	40
40	The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. Mucosal Immunology, 2019, 12, 733-745.	6.0	40
41	Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget, 2015, 6, 42183-42196.	1.8	40
42	Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 245-258.	1.3	39
43	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factorsâ€"Results from the Swiss IBD Cohort Study. American Journal of Gastroenterology, 2019, 114, 116-126.	0.4	39
44	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€"Disease Outcome and Response to Therapy. Journal of Crohn's and Colitis, 2021, 15, 1431-1442.	1.3	39
45	Dysbiotic microbiota interactions in Crohnâ€™s disease. Gut Microbes, 2021, 13, 1949096.	9.8	38
46	Protein Tyrosine Phosphatase Non-Receptor Type 22 Modulates NOD2-Induced Cytokine Release and Autophagy. PLoS ONE, 2013, 8, e72384.	2.5	38
47	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. Journal of Lipid Research, 2019, 60, 1270-1283.	4.2	37
48	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohnâ€™s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1292-1301.	1.3	37
49	Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis. PLoS ONE, 2013, 8, e73703.	2.5	36
50	Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohnâ€™s disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 114-118.	1.6	36
51	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. PLoS ONE, 2018, 13, e0199664.	2.5	35
52	Bilberry-Derived Anthocyanins Prevent IFN-γ-Induced Pro-Inflammatory Signalling and Cytokine Secretion in Human THP-1 Monocytic Cells. Digestion, 2014, 90, 179-189.	2.3	33
53	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. Journal of Experimental Medicine, 2021, 218, .	8.5	33
54	Protein Tyrosine Phosphatase Nonreceptor Type 2: An Important Regulator of Interleukinâ€6 Production in Rheumatoid Arthritis Synovial Fibroblasts. Arthritis and Rheumatology, 2015, 67, 2624-2633.	5.6	32

#	Article	IF	Citations
55	Role of Protein Tyrosine Phosphatases in Regulating the Immune System. Inflammatory Bowel Diseases, 2015, 21, 645-655.	1.9	32
56	The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. Inflammatory Bowel Diseases, 2018, 24, 1768-1779.	1.9	32
57	Permeability analyses and three dimensional imaging of interferon gamma-induced barrier disintegration in intestinal organoids. Stem Cell Research, 2019, 35, 101383.	0.7	32
58	Activation of pH-Sensing Receptor OGR1 (GPR68) Induces ER Stress Via the IRE1Î±/JNK Pathway in an Intestinal Epithelial Cell Model. Scientific Reports, 2020, 10, 1438.	3.3	32
59	The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS ONE, 2016, 11, e0155218.	2.5	31
60	Spermidine and spermine exert protective effects within the lung. Pharmacology Research and Perspectives, 2021, 9, e00837.	2.4	31
61	Celiac disease diagnosis still significantly delayed â€“ Doctor's but not patientsâ€™ delay responsive for the increased total delay in women. Digestive and Liver Disease, 2016, 48, 1148-1154.	0.9	30
62	The JAK Inhibitor Tofacitinib Rescues Intestinal Barrier Defects Caused by Disrupted Epithelial-macrophage Interactions. Journal of Crohn's and Colitis, 2021, 15, 471-484.	1.3	30
63	WNT2b Activates Epithelial-mesenchymal Transition Through FZD4: Relevance in Penetrating CrohnÂ´s Disease. Journal of Crohn's and Colitis, 2020, 14, 230-239.	1.3	29
64	The Role for Dickkopf-Homolog-1 in the Pathogenesis of Crohnâ€™s Disease-Associated Fistulae. PLoS ONE, 2013, 8, e78882.	2.5	28
65	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBDâ€”What, Why, and How. Journal of Crohn's and Colitis, 2021, 15, 1410-1430.	1.3	28
66	Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease. World Journal of Gastroenterology, 2016, 22, 1034.	3.3	28
67	A Role for Tumor Necrosis Factor and Bacterial Antigens in the Pathogenesis of CrohnÊ¼s Diseaseâ€“Associated Fistulae. Inflammatory Bowel Diseases, 2013, 19, 2878-2887.	1.9	27
68	Succinate Activates EMT in Intestinal Epithelial Cells through SUCNR1: A Novel Protagonist in Fistula Development. Cells, 2020, 9, 1104.	4.1	27
69	New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. Swiss Medical Weekly, 2018, 148, w14599.	1.6	27
70	Genetics and epigenetics of inflammatory bowel disease. Swiss Medical Weekly, 2018, 148, w14671.	1.6	27
71	Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International Journal of Epidemiology, 2019, 48, 385-386f.	1.9	26
72	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS ONE, 2019, 14, e0210436.	2.5	26

#	Article	IF	Citations
73	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. Maturitas, 2018, 110, 71-78.	2.4	25
74	Fatigue in inflammatory bowel disease and its impact on daily activities. Alimentary Pharmacology and Therapeutics, 2021, 53, 138-149.	3.7	25
75	Loss of protein tyrosine phosphatase N2 potentiates epidermal growth factor suppression of intestinal epithelial chloride secretion. American Journal of Physiology - Renal Physiology, 2010, 299, G935-G945.	3.4	24
76	Fistulizing Crohn's Disease. Clinical and Translational Gastroenterology, 2017, 8, e106.	2.5	24
77	The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. BMC Gastroenterology, 2019, 19, 2.	2.0	24
78	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. United European Gastroenterology Journal, 2020, 8, 1196-1207.	3.8	24
79	Association between Cogan's syndrome and inflammatory bowel disease: A case series. Journal of Crohn's and Colitis, 2011, 5, 64-68.	1.3	22
80	Coganâ€™s Syndrome in Patients With Inflammatory Bowel Disease â€“ A Case Series. Journal of Crohn's and Colitis, 2015, 9, 886-890.	1.3	22
81	Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterology Journal, 2016, 4, 669-676.	3.8	21
82	Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis. Mucosal Immunology, 2019, 12, 1336-1347.	6.0	21
83	Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986514.	3.2	20
84	Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 560-571.	1.9	20
85	Ingested nano- and microsized polystyrene particles surpass the intestinal barrier and accumulate in the body. NanoImpact, 2022, 25, 100374.	4.5	20
86	Stepwise Development of an in vitro Continuous Fermentation Model for the Murine Caecal Microbiota. Frontiers in Microbiology, 2019, 10, 1166.	3.5	19
87	Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis. Journal of Crohn's and Colitis, 2019, 13, 785-797.	1.3	19
88	Tracing colonic embryonic transcriptional profiles and their reactivation upon intestinal damage. Cell Reports, 2021, 36, 109484.	6.4	18
89	Microbial Sensing by the Intestinal Epithelium in the Pathogenesis of Inflammatory Bowel Disease. International Journal of Inflammation, 2010, 2010, 1-12.	1.5	17
90	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. Inflammatory Intestinal Diseases, 2020, 5, 109-116.	1.9	17

#	Article	IF	Citations
91	The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. United European Gastroenterology Journal, 2016, 4, 506-514.	3.8	16
92	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. Journal of Clinical Investigation, 2021, 131, .	8.2	16
93	Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 53-67.	3.7	16
94	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. PLoS ONE, 2019, 14, e0211554.	2.5	15
95	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflammatory Intestinal Diseases, 2021, 6, 1-10.	1.9	15
96	Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. Journal of Clinical Investigation, 2019, 129, 2527-2541.	8.2	15
97	Inhibition of integrin Î±vÎ²6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. , 2022, 10, e003465.		15
98	Patientsâ€™ perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe? â€“ a patient survey. Nutrition Journal, 2015, 14, 78.	3.4	14
99	The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300â€‰ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterology Journal, 2018, 6, 1007-1014.	3.8	14
100	Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance. Frontiers in Immunology, 2020, 11, 1856.	4.8	14
101	Novel Strategies to Prevent Total Parenteral Nutritionâ€Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. Molecular Nutrition and Food Research, 2021, 65, e1901270.	3.3	14
102	The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. Inflammatory Intestinal Diseases, 2017, 2, 131-138.	1.9	13
103	Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas. Journal of Crohn's and Colitis, 2019, 13, 798-806.	1.3	13
104	A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis. Inflammatory Intestinal Diseases, 2021, 6, 140-153.	1.9	13
105	The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation. Annals of the New York Academy of Sciences, 2012, 1257, 93-102.	3.8	11
106	Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing. Digestion, 2016, 93, 249-259.	2.3	11
107	The Role of Protein Tyrosine Phosphatases in Inflammasome Activation. International Journal of Molecular Sciences, 2020, 21, 5481.	4.1	11
108	Contribution of CD3+CD8- and CD3+CD8+ T Cells to TNF-Î± Overexpression in Crohn Diseaseâ€“Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells. Inflammatory Bowel Diseases, 2021, 27, 538-549.	1.9	11

#	Article	IF	Citations
109	Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110020.	3.2	11
110	Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflammatory Intestinal Diseases, 2016, 1, 172-181.	1.9	10
111	The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. Digestion, 2016, 93, 182-192.	2.3	10
112	A Symptomatic Coffee Bean: Acute Sigmoid Volvulus. Case Reports in Gastroenterology, 2017, 11, 348-351.	0.6	10
113	Transcriptional and Ultrastructural Analyses Suggest Novel Insights into Epithelial Barrier Impairment in Celiac Disease. Cells, 2020, 9, 516.	4.1	10
114	Knock-Out of Î²-Glucosidase 2 Has No Influence on Dextran Sulfate Sodium-Induced Colitis. Digestion, 2011, 84, 156-167.	2.3	9
115	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. Journal of Clinical Gastroenterology, 2018, 52, 25-29.	2.2	9
116	Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor-ÎºB in the Intestinal Epithelium. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 339-355.	4.5	9
117	Autoimmune susceptibility gene PTPN2 is required for clearance of adherent-invasive Escherichia coli by integrating bacterial uptake and lysosomal defence. Gut, 2022, 71, 89-99.	12.1	9
118	Î²6-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma. Clinical and Translational Gastroenterology, 2021, 12, e00395.	2.5	9
119	pH-Sensing G Protein-Coupled Receptor OGR1 (GPR68) Expression and Activation Increases in Intestinal Inflammation and Fibrosis. International Journal of Molecular Sciences, 2022, 23, 1419.	4.1	9
120	Validation of the â€˜United Registries for Clinical Assessment and Researchâ€™ [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 532-537.	1.3	8
121	AMPK mediates inhibition of electrolyte transport and NKCC1 activity by reactive oxygen species. American Journal of Physiology - Renal Physiology, 2019, 317, G171-G181.	3.4	8
122	Choice of Lipid Emulsion Determines Inflammation of the Gutâ€Liver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. Molecular Nutrition and Food Research, 2021, 65, e2000412.	3.3	8
123	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. PLoS ONE, 2016, 11, e0160215.	2.5	7
124	The role for protein tyrosine phosphatase non-receptor type 22 in regulating intestinal homeostasis. United European Gastroenterology Journal, 2016, 4, 325-332.	3.8	7
125	Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. BMJ Open, 2017, 7, e013477.	1.9	7
126	PTPN2 as a promoter of colon carcinoma via reduction of inflammasome activation. Molecular and Cellular Oncology, 2018, 5, e1465013.	0.7	7

#	Article	IF	Citations
127	Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation. PLoS ONE, 2018, 13, e0193003.	2.5	7
128	Genetic risk factors predict disease progression in Crohnâ€™s disease patients of the Swiss inflammatory bowel disease cohort. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095925.	3.2	7
129	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD â€“ Challenges and Future Directions. Journal of Crohn's and Colitis, 2021, 15, 1407-1409.	1.3	7
130	Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol. BMJ Open, 2022, 12, e061421.	1.9	7
131	Dying in Yoghurt: The Number of Living Bacteria in Probiotic Yoghurt Decreases under Exposure to Room Temperature. Digestion, 2011, 83, 13-17.	2.3	6
132	Loss of PTPN23 Promotes Proliferation and Epithelial-to-Mesenchymal Transition in Human Intestinal Cancer Cells. Inflammatory Intestinal Diseases, 2019, 4, 161-174.	1.9	6
133	Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. Microorganisms, 2021, 9, 1752.	3.6	6
134	Successful treatment of a proximal esophageal rupture with a luminal sponge. Endoscopy, 2015, 47, E293-E294.	1.8	5
135	Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. Case Reports in Gastroenterology, 2016, 10, 113-119.	0.6	5
136	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohnâ€™s disease patients. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1875771.	3.2	5
137	Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. PLoS ONE, 2019, 14, e0215738.	2.5	5
138	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2019, 25, 1357-1366.	1.9	5
139	Presence of PTPN2 SNP rs1893217 Enhances the Anti-inflammatory Effect of Spermidine. Inflammatory Bowel Diseases, 2020, 26, 1038-1049.	1.9	5
140	Loss of PTPN22 Promotes Intestinal Inflammation by Compromising Granulocyte-mediated Antibacterial Defence. Journal of Crohn's and Colitis, 2021, 15, 2118-2130.	1.3	5
141	Lower Risk of B1-to-pB3-Stage Migration in Crohnâ€™s Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. Digestive Diseases and Sciences, 2020, 65, 2654-2663.	2.3	4
142	Solute Carrier Family 12 Member 2 as a Proteomic and Histological Biomarker of Dysplasia and Neoplasia in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, 287-298.	1.3	4
143	Energy Drink Administration Ameliorates Intestinal Epithelial Barrier Defects and Reduces Acute DSS Colitis. Inflammatory Bowel Diseases, 2021, 27, 1139-1152.	1.9	4
144	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. Molecular Nutrition and Food Research, 2021, 65, e2000514.	3.3	4

#	Article	IF	Citations
145	Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. Inflammatory Bowel Diseases, 2021, 27, 1986-1998.	1.9	4
146	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. United European Gastroenterology Journal, 2021, 9, 773-780.	3.8	4
147	Mono Sodium Urate Crystal-induced Peritonitis for in vivo Assessment of Inflammasome Activation. Bio-protocol, 2018, 8, e2754.	0.4	4
148	Unravelling the Impact of the Genetic Variant rs1042058 within the TPL2 Risk Gene Locus on Molecular and Clinical Disease Course Patients with Inflammatory Bowel Disease. Cells, 2021, 10, 3589.	4.1	4
149	Su1261 Expression of Interleukins 22 and 33, Matrix Metalloproteinases 9 and 13, Mast Cell Markers and Hypoxia-Inducible Factor 1Î± in Crohn's Disease Associated Fistulae. Gastroenterology, 2013, 144, S-441-S-442.	1.3	3
150	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. Digestive and Liver Disease, 2017, 49, 268-272.	0.9	3
151	The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. Inflammatory Intestinal Diseases, 2020, 5, 170-179.	1.9	3
152	Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis. International Journal of Molecular Sciences, 2021, 22, 6820.	4.1	3
153	A distinct pattern of disease-associated single nucleotide polymorphisms in IBD risk genes in a family with Crohnâ€™s disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 803-806.	1.6	2
154	Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628481989521.	3.2	2
155	Titanium Dioxide Presents a Different Profile in Dextran Sodium Sulphate-Induced Experimental Colitis in Mice Lacking the IBD Risk Gene Ptpn2 in Myeloid Cells. International Journal of Molecular Sciences, 2021, 22, 772.	4.1	2
156	Fucosylation and Sialylation of Fc-Fragment of anti-Tumour Necrosis Factor Alpha Antibodies do not Influence Their Immunogenicity in Monocyte-Derived Dendritic Cells. Journal of Crohn's and Colitis, 2021, 15, 1596-1601.	1.3	2
157	Efficient treatment of esophageal nutrition bezoars: dissolution outmatches removalâ€”the Zurich approach. Clinical Journal of Gastroenterology, 2021, 14, 1602-1606.	0.8	2
158	From Patient Material to New Discoveries: a Methodological Review and Guide for Intestinal Stem Cell Researchers. Stem Cell Reviews and Reports, 2022, 18, 1309-1321.	3.8	2
159	Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. Inflammatory Intestinal Diseases, 2017, 2, 211-218.	1.9	1
160	Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation. Leukemia and Lymphoma, 2019, 60, 685-695.	1.3	1
161	Deletion of Protein Tyrosine Phosphatase Nonreceptor Type 2 in Intestinal Epithelial Cells Results in Upregulation of the Related Phosphatase Protein Tyrosine Phosphatase Nonreceptor Type 23. Inflammatory Intestinal Diseases, 2019, 4, 14-26.	1.9	1
162	Response to Al Sulais et al.. American Journal of Gastroenterology, 2019, 114, 1346-1347.	0.4	1

#	Article	IF	Citations
163	Protein Tyrosine Phosphatase Nonreceptor Type 2 Expression Does Not Correlate with Viral Load or Response to Direct-Acting Antiviral Therapy in Hepatitis C Virus Infections-Infected Patients. Digestion, 2021, 102, 453-461.	2.3	1
164	Perianal fistulodesis â€“ A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae. World Journal of Gastrointestinal Surgery, 2021, 13, 187-197.	1.5	1
165	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. Ecological Management and Restoration, 2021, 34, .	0.4	1
166	What Distinguishes Mechanisms of Fistula and Stricture Formation. , 2018, , 307-317.		1
167	MMP9 expression in intestinal fistula from patients with fistulizing CD and from human xenograft mouse model. Tissue Barriers, 2021, , 1994350.	3.2	1
168	Inhibition of Adenosine Monophosphateâ€activated Protein Kinase (AMPK) ameliorates the effects of Interferon gamma (IFN gamma) on epithelial barrier function in T84 cells. FASEB Journal, 2008, 22, 1189.10.	0.5	0
169	Interferonâ€gamma (IFN Î³) induced epithelial barrier dysfunction in T84 human intestinal epithelial cells (IECs) occurs via phosphatidylinositol 3â€kinase (PI3â€K) mediated activation of adenosine monophosphateâ€activated protein kinase (AMPK). FASEB Journal, 2009, 23, 978.2.	0.5	0
170	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. BMC Gastroenterology, 2021, 21, 310.	2.0	0
171	Loss of PTPN2 Activity Alters Iron Handling Protein Expression in IBD Patients and Causes Iron Deficiency in Mice. FASEB Journal, 2022, 36, .	0.5	0
172	Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model.. Journal of Clinical Oncology, 2022, 40, 2565-2565.	1.6	0